menu
    • menu

    Company profile for Neuronascent

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using...
    Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NeuronascentUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    6030 Day Break Circle A150 – PMB244 Clarksville, MD 21029
    Telephone
    Telephone
    +1 240-876-7496
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://neuronascent.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/neuronascent-inc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Neuronascent NNI-362 Ph1a Results Published; FDA Waives Fee
    Neuronascent NNI-362 Ph1a Results Published; FDA Waives Fee

    13 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/13/3132372/0/en/Neuronascent-Announces-Progress-for-Lead-Candidate-NNI-362-Publication-of-Phase-1a-Clinical-Trial-Results-and-FDA-Grants-Waiver-of-Fee-for-Canine-Cognitive-Disorder-2025-Submission.html

    GLOBENEWSWIRE
    13 Aug 2025
    Share Share
    Neuronascent to Present New Parkinson™s Model Data at AAIC 2023 for NNI-362
    Neuronascent to Present New Parkinson™s Model Data at AAIC 2023 for NNI-362

    28 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/28/2695973/0/en/Neuronascent-to-Present-New-Parkinson-s-Model-Data-at-AAIC-2023-for-the-Alzheimer-s-Disease-Investigational-Therapy-NNI-362.html

    GLOBENEWSWIRE
    28 Jun 2023
    Share Share
    Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022
    Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022

    08 Nov 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/11/08/2550583/0/en/Neuronascent-to-Present-Further-NNI-362-Phase1a-Data-at-CTAD-2022-for-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    08 Nov 2022
    Share Share
    Neuronascent Receives FDA ODD for NNI-351 Treatment of Fragile X Syndrome
    Neuronascent Receives FDA ODD for NNI-351 Treatment of Fragile X Syndrome

    01 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/01/2453975/0/en/Neuronascent-Receives-FDA-Orphan-Drug-Designation-for-NNI-351-Treatment-of-Fragile-X-Syndrome.html

    GLOBENEWSWIRE
    01 Jun 2022
    Share Share
    Neuronascent Receives FDA RPD Designation for NNI-351 for Fragile X Syndrome
    Neuronascent Receives FDA RPD Designation for NNI-351 for Fragile X Syndrome

    24 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/24/2449058/0/en/Neuronascent-Receives-FDA-Rare-Pediatric-Drug-Designation-for-NNI-351-Treatment-for-Fragile-X-Syndrome.html

    GLOBENEWSWIRE
    24 May 2022
    Share Share
    Neuronascent Releases Further Positive Results of NNI-362 in Phase 1a Trial
    Neuronascent Releases Further Positive Results of NNI-362 in Phase 1a Trial

    30 Mar 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/03/30/2412617/0/en/Neuronascent-Releases-Further-Positive-Results-of-NNI-362-in-A-Randomized-Phase-1a-Trial-for-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    30 Mar 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search